Advances in research on the correlation between LTCCBs and cardiovascular diseases: A review

The prevalence of cardiovascular diseases has been rising globally, and various therapies have made significant strides in controlling the progression of these conditions and improving prognosis. Among these, pharmacological therapies have evolved rapidly and are increasingly integrated into clinical practice. Pharmacological treatments play a pivotal role in both basic research and clinical applications, particularly in deriving accurate conclusions from drug-related trials to address clinical challenges in drug selection and improve the cure rates of various diseases. L-type calcium channel blockers (LTCCBs) have attracted considerable research attention in recent years. With the accelerated development of novel drugs, the range of LTCCBs-based drug types has also diversified. This review aims to explore the relationship between LTCCBs and conditions such as hypertension, arrhythmias, ischemia-reperfusion injury, and cardiomyopathy, with the goal of contributing to the diversification of treatment options for cardiovascular diseases patients. Additionally, it seeks to establish a theoretical foundation for future research and the clinical application of these therapies. It is imperative to conduct a thorough analysis and in-depth discussion regarding the deficiencies in the medication process as well as various application scenarios. With the advancement of science and the introduction of novel drugs into clinical practice, it is anticipated that these developments will play a critical guiding role in the diagnosis and treatment of complex clinical diseases.